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SUMMARY
Classification studies with high-dimensional measurements and relatively small sample sizes are increas-
ingly common. Prospective analysis of the role of sample sizes in the performance of such studies is
important for study design and interpretation of results, but the complexity of typical pattern discovery
methods makes this problem challenging. The approach developed here combines Monte Carlo meth-
ods and new approximations for linear discriminant analysis, assuming multivariate normal distributions.
Monte Carlo methods are used to sample the distribution of which features are selected for a classifier
and the mean and variance of features given that they are selected. Given selected features, the linear
discriminant problem involves different distributions of training data and generalization data, for which 2
approximations are compared: one based on Taylor series approximation of the generalization error and
the other on approximating the discriminant scores as normally distributed. Combining the Monte Carlo
and approximation approaches to different aspects of the problem allows efficient estimation of expected
generalization error without full simulations of the entire sampling and analysis process. To evaluate the
method and investigate realistic study design questions, full simulations are used to ask how validation
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error rate depends on the strength and number of informative features, the number of noninformative fea-
tures, the sample size, and the number of features allowed into the pattern. Both approximation methods
perform well for most cases but only the normal discriminant score approximation performs well for cases
of very many weakly informative or uninformative dimensions. The simulated cases show that many real-
istic study designs will typically estimate substantially suboptimal patterns and may have low probability
of statistically significant validation results.
Keywords: Biomarker discovery; Experimental design; Generalization error; Genomic; Pattern recognition; Proteomic.
1. INTRODUCTION
Recent years have seen an explosion of work on classification problems where the number of measured
features per sample is vastly greater than the number of samples. For biological classification problems,
such data arise from genomic DNA microarrays and proteomic mass spectrometry assays, from which
investigators try to classify disease categories, tumor types, response to drugs, or other categories (Ludwig
and Weinstein, 2005). Most of the efforts in method development have appropriately focused on what to do
with real data sets (Wang and Shen, 2006; Adam and others, 2002). Generally speaking, various methods
must select features (sometimes called biomarkers) to be used for classification and estimate a classifier
without over-fitting to the many available data dimensions.
Because of the complexity of the algorithms involved, it is not straightforward to answer questions
about study design. For example, if there are 10 informative and 5000 noninformative features and the
best possible classification error rate is 5%, how many samples are necessary to have an 80% chance
of estimating a classifier with less than 10% error rate for independent validation samples? Or, how
many samples are necessary so that with probability 95%, the estimated classifier will perform statis-
tically significantly better than a 50% error rate for independent validation samples, that is, conclude
the study has at least found something nonrandom? Investigators planning studies have access to sound
statistical principles but few specifics to serve as guideposts in evaluating sample sizes relative to hy-
pothesized outcomes. Analysis of study design for high-dimensional classification studies has been iden-
tified as an important problem for genomics and proteomics because significant resources are required to
execute such studies (Dobbin and Simon, 2007; Allison and others, 2006; Pusztai and Hess, 2004; Hwang
and others, 2002).
Issues of sample size for genomic and proteomic pattern discovery studies are potentially quite
important. Over 60 proteomics discovery studies have been published in recent years (Coombes and
others, 2005; Baker, 2005). Many have sample sizes in the approximately 10–20 range; some notable
cases with higher sample sizes (e.g. Adam and others, 2002; Petricoin, Ardekani, and others, 2002;
Petricoin, Ornstein, and others, 2002; Zhang and others, 2004; Rogers and others, 2003) reveal that in
broad terms, sample sizes of ∼ 50 per group are rare and of ∼ 100 per group are very rare. Implicit
in some rationales for biomarker discovery studies is the possibility that multiple, individually weak
biomarkers could combine to form a collectively strong diagnostic pattern. The observation that discovery
studies often find nonspecific markers (Baker, 2005) also suggests that disease-specific patterns may re-
quire multiple, individually weak biomarkers. Detecting patterns of multiple weak biomarkers amid many
noninformative data dimensions may require substantially greater sample sizes than detecting individually
strong biomarkers.
In proteomics, early biomarker discovery and validation studies (Petricoin, Ardekani, and others,
2002; Petricoin, Ornstein, and others, 2002; Petricoin and Liotta, 2003; Rogers and others, 2003; Adam
and others, 2002; Li and others, 2002; Adam and others, 2001) led to renewed attention toward poten-
tial pitfalls of design and analysis methods. These include low discovery and validation sample sizes,
uncertainty about data preprocessing and statistical methods, low sample processing and measurement
reproducibility within and between study sites, uncertainty about the biological nature and consistency
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of patterns, and lack of independent validation studies (Sorace and Zhan, 2003; Diamandis, 2004a,b;
Listgarten and Emili, 2005; Coombes and others, 2005; Ebert and others, 2006; Wilkins and others,
2006). Similar issues have been raised for genomic studies (e.g. Pusztai and Hess, 2004; Ludwig and
Weinstein, 2005). Two important studies notable for their independent validation trials highlight the
possibility—among many possible reasons for low validation success—that small sample sizes have been
fundamentally limiting. Rogers and others (2003) saw sensitivity for renal cancer decline from ∼ 100%
in discovery to ∼ 40% in validation, and Zhang and others (2004) saw specificity decline from ∼ 90% in
discovery to ∼ 65% in validation.
For prospective analysis of pattern discovery study designs, purely simulation approaches quickly
become cumbersome because there are many scenarios of interest, but purely analytical results are not
easy to obtain. We take a middle road between simulations and approximations, with Monte Carlo meth-
ods for the feature-selection step and approximations for generalization error rates given each feature
set. We use multivariate normal data and linear discriminant classification of features selected by uni-
variate tests. While biologically simplistic, this framework captures the key impacts of both inaccurate
feature selection and inaccurate classifier estimation. Related studies that use multivariate normal mod-
els include Pepe and others (2003), Hu and others (2005), Jung (2005), and Dobbin and Simon (2007),
among others. Our approach gives order-of-magnitude faster estimation of generalization error compared
to direct simulations, which are given for comparison. Both full simulation and simulation–approximation
results are useful, but the latter can facilitate more practical exploration of study designs. Our approach
also gives insight into which sources of variation are most important and suggests directions for future
improvements.
We evaluate the simulation–approximation approach by comparing it to complete simulations that ad-
dress meaningful study design questions (supplementary material available at Biostatistics online, http:
//www.biostatistics.oxfordjournals.org). We ask how validation error rate depends on the strength and
number of informative features (and hence the minimum possible error rate), the number of noninformative
features, the patient sample size, and the number of features allowed into the pattern. We find that typi-
cal sample sizes may perform poorly when there is a true pattern composed of many individually weak
features. This result is not surprising based on general principles, but moving from principles to specific
examples as guideposts is important for design of real studies.
We also give 2 approximations of the generalization (or test, or validation) error of a linear discrimi-
nant classifier when the training and validation samples do not follow the same distributions. The first is
a delta approximation, from Taylor expansions of generalization error around the expected discriminant
boundary. The second, and more successful, approximates the discriminant scores as normally distributed.
Approximations of linear discriminant analysis with training and generalization samples from the same
distributions have been reviewed by McLachlan (1992) and Wyman and others (1990). According to
Wyman and others (1990) and Viollaz and others (1995), normal approximations of discriminant scores
seem to be more accurate than other approaches, consistent with our results.
A related approach was given by Dobbin and Simon (2007), but ours appears to be more general and
accurate (at the expense of being more computational). Theoretical bounds on generalization error from
machine learning theory give another path of investigation (Hastie and others, 2001). For the related goal
of identifying individually significant data dimensions (features), much study design work has built on
feature-by-feature false discovery rate ideas (Benjamini and Hochberg, 1995; Storey, 2002; Efron, 2007).
Feature-by-feature metrics of study design efficacy include the expected discovery rate (Gadbury
and others 2004), anticipated average power (Pounds and Cheng, 2005), expected number of false dis-
coveries (Tsai and others, 2005), and probability of informative features ranking highly (Pepe and others,
2003). Numerous recent studies give methods for feature selection or estimation of generalization error
given real data, as opposed to prospective study design (e.g. Mukherjee and others, 2003; Fu and others,
2005; Wang and Shen, 2006).
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2. PROBLEM DEFINITION
Consider samples of size n j for each of J classes ( j ∈ {1, . . . , J }), with each sample having M dimen-
sions. By a high-dimensional classification problem, we mean M  n, where n = ∑Jj=1 n j is the total
sample size. For the training samples, from which the classifier will be estimated, let xi j ∈ RM be the
data vector for the i th sample of class j . Let X j be all the data for class j and X be all the training data.
Let the number of dimensions of the data distributions that are truly informative (i.e. differ between
classes) be M I and those that are truly uninformative be MU, with M = M I + MU. In the examples
below, we will for simplicity use J = 2 and group means centered around 0 with all variances equal to 1.
Let  be the vector of differences between class means for the informative dimensions, so the means
from group 1 are
(−0.5, 0MU) and the means from group 2 are (0.5, 0MU), where 0MU is a length
MU vector of zeros. In this notation, a true pattern is defined by (, MU) and a study design scenario is
defined by (, MU, n), where n = (n1, n2).
A classifier ψ(xG |X) predicts the class, j ∈ 1, . . . , J , of a new (generalization or validation) sample
xG based on the training data, X. The generalization sample comes from one of the same distributions (for
its unknown class) as the training samples. Define the conditional generalization error for class j as the
expected fraction of incorrect classifications for a new sample, xG j , from class j given a training sample X,
CG j (, MU|X) = E j [I (ψ(xG j |X) = j)], (2.1)
where the expectation is over xG j sampled from true distribution j and the indicator function I (B) is 1 if
B is true and 0 otherwise.
Define the conditional generalization error across all classes as
CG(, MU|X) =
∑
j
P( j)CG j (, MU|X), (2.2)
where P( j) is the probability that a new sample is from class j .
The generalization error for a new sample from group j is the conditional generalization error averaged
over training samples:
G j (, MU, n) = ET[CG j (, MU|X)], (2.3)
where ET denotes expectation over training samples, X, with sample sizes n. Finally, the overall general-
ization error is
G(, MU, n) =
∑
j
P( j)G j (, MU, n). (2.4)
Given a generalization sample XG , with replicate data xG j from groups j = 1, 2, and a classifica-
tion procedure ψ(xG |X), define the “pattern discovery power” as the expected probability of rejecting
the null hypothesis that the predictions ψ(xG j |X) are independent of the true class labels, using an ap-
propriate statistical test, with expectations over both the training and generalization samples. This is the
probability that the independent validation step of an entire study concludes that the estimated classifier
is at least better than random. This paper focuses on calculating generalization error rather than pattern
discovery power, but the latter relates to one of the ultimate judgments about a study—whether something
nonrandom has been independently validated—and is represented graphically with the simulation results.
3. SIMULATION–APPROXIMATION OF GENERALIZATION ERROR
Next, we give a joint simulation and approximation approach to estimate efficiently the generalization
error rates CG j and G j for multivariate normal data analyzed with linear discriminant analysis. Define a
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partition of the space of X samples into R nonoverlapping regions, 1, . . . , R , that determine which di-
mensions of X are selected to estimate the classifier, that is, the feature selection. Define δ = (δ1, . . . , δM )
to be a vector of 0s and 1s, with δk = 1 if dimension k will be used for classification and 0 if not. For all
X ∈ r , the same dimensions of X are used by the classifier (so R  2M ), so it makes sense to write δ as
a function of r : δr ≡ δ(r ).
The generalization error for class j can be factored as
G j (, MU, n) =
R∑
r=1
P(X ∈ r )ET[CG j (, MU|X)|X ∈ r ], (3.1)
where P(·) is the probability indicated by its argument.
We develop approximations for ET[CG j (, MU|X)|X ∈ r ] based on the first 2 moments of P(X|X
∈ r ), the probability density of training data sets given that they lead to feature selection δr . This is
an expected generalization error given that the training and generalization samples do not come from
the same distributions. We use Monte Carlo samples to estimate P(X ∈ r ) and the first 2 moments of
P(X|X ∈ r ), which can be generated efficiently. In what follows,  ∈ {1, . . . , R}.
In a real analysis, feature selection is intertwined with the problem of how many features to include,
which is one type of regularization parameter that may be optimized over data-based estimates of gen-
eralization error, such as cross-validation. From the study design point of view, the goal is to provide
insight into typical study outcomes under various scenarios. Instead of trying to include optimization
of the number of features within each approximation, we calculate the approximation across a range of
the feature-selection thresholds. This does not include variation or suboptimality in the feature-selection
threshold in our estimates of generalization error distributions, but it does offer insight about the sensiti-
vity of generalization error to the feature-selection threshold, which provides context and builds intuition
for interpreting results with real data.
3.1 Monte Carlo approximation of feature selection
Next, we show how P(X ∈ ) and the mean and variance of P(X|X ∈ ) can be estimated with Monte
Carlo methods. In the examples here, we assume feature selection is based on feature-by-feature univariate
t-tests, which, when the data dimensions really are independent, makes the analysis optimistic because it
“knows” this aspect of the “truth.” It is common to use feature-by-feature hypothesis tests to estimate false
discovery rates as part of analyzing a high-dimensional study, so this simplification allows our results to
stand side-by-side with expected false discovery rates and related ideas in considering study designs.
Consider a single data dimension, k, which may or may not be truly informative, for which δk will be
1 if the dimension is selected for the pattern and 0 if not. Let xi jk be the kth dimension of sample i from
class j . Let the n1 and n2 samples from groups j = 1 and j = 2, respectively, be normally distributed in
dimension k: xi1k ∼ N (−0.5k, σ 2 = 1), xi2k ∼ N (0.5k, σ 2 = 1). Suppose the decision to include
feature k in classification is based on the P-value of a t-test. One calculates µˆ jk = n−1j
∑n j
i=1 xi jk for
j = 1, 2; s2k = df−1s
∑2
j=1
∑n j
i=1(xi jk − µˆ jk)2, where dfs = n1 + n2 − 2 are the degrees of freedom
of s2k ; and tk = (µˆ2k − µˆ1k)/(sk
√
n−11 + n−12 ). The feature is included if |tk | > t1−Pc/2,dfs , where Pc is
a threshold significance level for choosing δk = 1 and t1−Pc/2,dfs is the inverse cumulative t-density at
1 − Pc/2 with dfs degrees of freedom.
It is equivalent to consider the 2 independent random variables
z = (µˆ2k − µˆ1k)
σ
√
1
n1
+ 1
n2
∼ N
⎛
⎝ k
σ
√
1
n1
+ 1
n2
, 1
⎞
⎠ (3.2)
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and e2 = s2k /σ 2 ∼ χ2dfs . Then,
P(δk = 1) =
∫
P(z)P(e2)I
(
|z|√
e2/dfs
> t1−Pc/2,dfs
)
dz de2 (3.3)
and
E[g(z, e2)|δk = 1] =
∫
g(z, e2)P(z)P(e2)I
( |z|√
e2/dfs
> t1−Pc/2,dfs
)
dz de2
P(δk = 1) . (3.4)
Using g(z, e2) = σ z
√
n−11 + n−12 or g(z, e2) = σ 2e2/dfs in (3.4) gives an estimate of the mean difference
between groups 1 and 2 or the within-group variance, respectively, given that the t-test is significant.
Working with the densities of z and e2 allows more efficient numerical methods to estimate (3.3) and
(3.4) than if one worked with the densities of xi jk directly. Next, 2 possible Monte Carlo implementations
are given, but a variety of numerical methods could be used. For the case of a t-test, (3.3) is simply a
cumulative density of a noncentral t-distribution with noncentrality parameter k/(σ
√
n−11 + n−12 ) and
dfs degrees of freedom. For a Monte Carlo estimate of (3.4), define {z(l), e2,(l)}, l = 1, . . . , m, to be a
simulated sample from P
(
z, e2|I (|z|√dfs/e2 > t1−Pc/2,dfs )), which can be generated efficiently with a
Markov chain Monte Carlo (MCMC) algorithm. Then, a Monte Carlo estimate of (3.4) is
Eˆ[g(z, e2)|δk = 1] = 1
m
m∑
l=1
g(z(l), e2,(l)). (3.5)
Even a small sample (by MCMC standards) of say m = 100 can be reasonable for (3.5).
If one chose to extend the basic idea here for a test for which values of (3.3) are not as easily available
as a noncentral t-distribution, then both (3.3) and (3.4) could be estimated by Monte Carlo. For that case,
redefine {z(l), e2,(l)}, l = 1, . . . , m, to be a Monte Carlo sample of size m from P(z, e2). Then, the natural
estimates of (3.3) and (3.4) are
Pˆ(δk = 1) = 1
m
m∑
l=1
I
(
|z(l)|√
e2,(l)/dfs
> t1−Pc/2,dfs
)
(3.6)
and
Eˆ[g(z, e2)|δk = 1] = 1
m Pˆ(δk = 1)
m∑
l=1
g(z(l), e2,(l))I
(
|z(l)|√
e2,(l)/dfs
> t1−Pc/2,dfs
)
. (3.7)
Extensions based on other Monte Carlo numerical integration techniques (such as importance sampling)
are straightforward and not our focus here.
3.2 Approximations for generalization error
Let  be the parameter vector of the classification function ψ , a linear discriminant function in the ex-
amples here. An estimated classifier ψ(xG j |X) is defined by estimated parameters ˆ = ˆ(X). For more
concise notation, we view generalization error as a function of ˆ, that is, CG j (, MU|X) = CG j (ˆ).
Delta approximation. A delta approximation for the class generalization error given X ∈  is
ET[CG j (ˆ)|X ∈ ] ≈ CG j (E[ˆ|X ∈ ]) + 0.5
p∑
r,s=1
Cov(ˆr , ˆs |X ∈ )∂rsCG j (E[ˆ|X ∈ ]),
(3.8)
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where ∂rs(CG(E[ˆ|X ∈ ])) is the second derivative of CG j with respect to r and s evaluated at
E[ˆ|X ∈ ], Cov(ˆr , ˆs |X ∈ ) is the covariance between the r and the s dimensions of ˆ|X ∈ ,
and p is the number of features selected due to X ∈ . The delta approximation is derived by Taylor
series expansion of the expectation integral around E[ˆ|X ∈ ]. Note that although the dimensions (or
features) are assumed to be independent for feature selection, after they are selected they are approximated
as multivariate normal, so the covariances in (3.8) are not necessarily zero.
Normal score approximation. Classifiers typically involve a continuous score function, d(xG j |ˆ), with
prediction of group 1, ψ(xG j |X) = 1, if d(xG j |ˆ) < 0 (by convention here) and prediction of group
2, ψ(xG j |X) = 2, if d(xG j |ˆ) > 0. The normal score approximation is to treat d(xG j |ˆ) as normally
distributed with mean E[d(xG j |ˆ)] and variance V [d(xG j |ˆ)]. Then,
ET[CG j (ˆ)|X ∈ ] ≈ 	
⎛
⎝u j E[d(xG j |ˆ)]√
V [d(xG j |ˆ)]
⎞
⎠ , (3.9)
where u1 = +1, u2 = −1, and 	(·) is the standard normal cumulative density function.
Relation to linear discriminant theory. For the case that ψ is a linear discriminant function, we need
to calculate E[ˆ|X ∈ ] and Cov(ˆr , ˆs |X ∈ ) for the delta approximation and E[d(xG j |ˆ)] and
V [d(xG j |ˆ)] for the normal score approximation. Define xFi j to be the selected training features (i.e.
given X ∈ ) of the i th sample from class j . It is convenient to arrange the signs of the data in a
consistent manner, so we assume (without loss of generality) that whenever dimension k is included
in the classifier, µˆ2k > µˆ1k (i.e. if µˆ2k < µˆ1k , reverse the signs of the data). Then, define µF j and

 F to be the mean vector and covariance matrix of xFi j , respectively. The difference between means
is F = µF2 − µF1. By symmetry, µF1 + µF2 = 0. The distributions of the xFi j will not typically
be normal because they are conditioned on a significant difference between normal sample means, but
the approximation below uses exact expressions (see supplementary material available at Biostatistics
online) for E[ˆ|X ∈ ], Cov(ˆr , ˆs |X ∈ ), E[d(xG j |ˆ)], and V [d(xG j |ˆ)] under the assumption
that the distributions are normal. The expressions use results of Siskind (1972) on the second moments
of inverse Wishart distributions, which are related to the sampling distribution of 
ˆ−1F . This allows full
incorporation of multivariate sampling variability in estimating the linear discriminant classifier and uses
the principle that second moment–based approximations derived from normal theory are often reasonable.
Thus, there are really 2 approximations happening: an approximation of training features (given they have
been selected) as multivariate normally distributed and either the delta approximation or normal score
approximation of generalization error.
3.3 Linear discriminant analysis when the training and validation samples follow different distributions
As above, define a training sample of xFi1 ∼ N (µF1, 
 F ), i = 1, . . . , n1, from class 1 and xFi2 ∼
N (µF2, 
 F ), i = 1, . . . , n2, from class 2. Define F = µF2 − µF1, with F > 0 in every dimension.
Define the “true” parameters of ψ in the linear discriminant case as  = (w, a), where w = 
−1F F and
a = 0.5(µF1 + µF2) = 0. These are estimated by wˆ = 
ˆ−1F ˆF , where

ˆ F =
∑n1
i=1(xFi1 − µˆF1)(xFi1 − µˆF1)′ +
∑n2
i=1(xFi2 − µˆF2)(xFi2 − µˆF2)′
n1 + n2 − 2 (3.10)
is the pooled unbiased estimate of 
 F , ˆF = µˆF2 −µˆF1, aˆ=0.5(µˆF1 +µˆF2), and µˆF j =n−1j
∑n j
i=1 xFi j .
This is the setup of standard linear discriminant analysis (McLachlan, 1992).
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Define a validation sample from class j as xG j ∼ N (µG j , 
G). The discriminant score for a value
xG is
d(xG |ˆF ) = wˆ′(xG − aˆ) − log
(
P(1)
P(2)
)
(3.11)
with prediction of class 1 for d(xG |ˆ) < 0 and class 2 for d(xG |ˆ) > 0. If the training and validation
samples came from the same distributions, then w and a would give the optimal discriminant function.
We maintain the generality of the prior log-odds ratio, log(P(1)/P(2)), in the derivations. In the sim-
ulations below, we assume P(1) = P(2). These values may be very different for a population screening
test, where only a very small fraction is expected to have a disease condition, compared to a problem such
as disease classification given disease presence. Consideration of P(1) = P(2) is standard in balancing
sensitivity and specificity of medical tests.
To use the delta approximation (3.8), we need the first 2 moments of wˆ and aˆ and the derivatives of
the generalization error with respect to the elements of wˆ and aˆ. To use the normal score approximation
(3.9), we need the first 2 moments of d(xG |ˆF ). These are given exactly in the supplementary material
available at Biostatistics online for the approximation that the training samples are normally distributed
given that the selected dimensions were individually significant.
3.4 Summation over feature spaces
It remains to complete the calculation (3.1) efficiently by combining the Monte Carlo estimates of (3.3)
and (3.4) and the approximations (3.8) or (3.9). If the space of features that might be selected is relatively
simple, then one might directly enumerate cases where P(X ∈ ) is appreciably greater than zero; this
is not stated mathematically here. More generally, one can use a Monte Carlo sample from the space of
selected features to approximate (3.1).
Let {(l)}, l = 1, . . . , m, be a sample from P() ≡ P(X ∈ ). Corresponding to each partition piece
, there is a distribution P(X|X ∈ ). Since this is characterized by F and 
 F (estimated by (3.5)),
we denote P(X|X ∈ (l)) ≈ P(X|(l)F , 
(l)F ). Then, the Monte Carlo approximation of (3.1) is
Gˆ j (, MU, n) = 1
m
m∑
l=1
ET[CG j (, MU|X)|(l)F , 
(l)F ]. (3.12)
For feature-by-feature selection as discussed above, the relationship δr = δ(r ), r = 1, . . . , R, is one-
to-one, so we can identify P(δr ) ≡ P(r ). Then, sampling from P() in practice amounts to simulating
on a feature-by-feature basis whether each feature is selected.
3.5 Choice of feature-selection thresholds
The above simulation and approximation steps require a choice for the P-value cutoff, Pc, used for fea-
ture selection. In practice, one can consider a range of Pc-values based on heuristic considerations to
encompass the value of Pc that minimizes the expected validation error. In the simulation results here
(supplementary material available at Biostatistics online, summarized below), the following heuristics
perform well. The lower bound PL of Pc is set to the value at which the probability of zero true discov-
eries is 30% because excluding most or all informative features will not lead to good patterns. The upper
bound PU of Pc is the minimum of 2 values. The first is the Pc level at which the probability of including
all informative features equals 80%, on the rationale that after including most or all informative features,
error rates will only get worse as false features are added. The second is the Pc such that the expected
number of uninformative features is N/2 − M I, that is, the expected total number of features if all truly
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informative features are included should not exceed N/2. In scenarios where the second bound was lower
than the first, higher Pc would lead to worse validation error rates due to many uninformative features.
3.6 Summary of simulation–approximation method
In summary, the simulation–approximation procedure uses the following steps:
1. Choose , MU, and n to define a study scenario.
2. Choose a useful range of feature-selection thresholds, Pc, which influence how many features are
chosen in the feature-selection stage.
3. For each (unique) dimension of  and each Pc, use the noncentral t-distribution and/or Monte
Carlo methods to estimate
a) the probability that the feature will be selected,
b) the expected within-group variances and difference between group means given that the fea-
ture is selected.
4. For the Monte Carlo approximation (3.12), generate a sample of training feature combinations,
{(l)}, for which the generalization error will be approximated.
5. For each training feature combination, use the variances and mean differences given that the features
are selected to approximate the generalization error using either (3.8) or (3.9) with the calculations
in the supplementary material available at Biostatistics online.
6. Sum the terms in (3.12).
4. SIMULATION STUDY
Results of simulations of 7 realistic study designs are detailed in the supplementary material available at
Biostatistics online. The first 6 scenarios consider optimal (i.e. Bayes) error rates of 0.05, 0.10, and 0.20
with either 3 (few strong) or 12 (many weak) truly informative dimensions, while the seventh considers
optimal error of 0.05 from 46 (very many, very weak) dimensions. All scenarios use equal discovery
sample sizes for control and disease groups, n1 = n2, with the same mean difference for all informative
dimensions and 10 patients per group for validation power. The simulation–approximation is accurate
with the normal score approximation in all scenarios and with the delta approximation in all scenarios
except for very many, very weak true features. Both methods are most accurate when most of the varia-
tion in generalization error is due to variation in which features are selected rather than in discriminant
parameters given the feature space. Much larger numbers of truly informative dimensions would render
the approximations inaccurate, and, moreover, suggest methods beyond basic linear discriminant analysis
(LDA), such as shrinkage methods to constrain high variances in estimated patterns.
Several realistic scenarios have limited statistical power for validation and lead to substantially sub-
optimal patterns. With 12 informative and 2000 uninformative features and optimal error rate of 20%,
sample sizes of 20, 50, and 100 give median validation error rates around 48%, 40%, and 30–35%, re-
spectively, with only sample sizes of 100 giving better than 50% power for validation. If the features give
optimal error rate of 10%, then 50 patients per group give high validation power but with median error
rates of roughly 18–22% for 1000–5000 uninformative dimensions. With an optimal error rate of 5%, 20
samples would give roughly 50–80% validation power at 5% significance for 1000–5000 uninformative
dimensions.
For a given optimal error rate, it is much harder to find patterns from many weak than from few strong
informative features. Given optimal error rate of 20%, 50 patients per group for 3 strong features give
better results than 100 patients per group with 12 weak features. For optimal error rate of 10% or 5%, 20
Classification study design 433
patients per group for 3 strong features give roughly comparable performance to 50 patients per group for
12 weak features. In summary, by far the strongest factors in pattern discovery power are sample size and
individual feature strength. Some of these results are sobering in light of sample sizes in typical studies.
It is plausible that some real studies to discover diagnostic patterns from high-dimensional assays could
have low power for independent validation and find patterns far from the best true pattern.
5. DISCUSSION
Prospective analysis of study design for high-dimensional pattern discovery is important to plan studies
with reasonable expectations of success based on scientific guesswork about the types of real patterns that
might exist. The complexity of feature selection and pattern analysis methods raises many challenges for
prospective study design. Here, we have explored a middle road between simulation and approximation,
with simulations to handle variability in the selected features and an approximation of linear discriminant
analysis given that the selected features appear to be informative in training data.
One of the most complicated ways in which the scenarios here may be optimistic is their lack of mul-
tivariate patterns and pattern recognition methods. Multivariate patterns could include correlated features
that appear to be individually weak but are collectively strong or even harder possibilities such as the clas-
sic “XOR” (checkerboard) problem, where each marginal distribution has no information and only more
complicated models than LDA can represent the pattern. In such problems, the hazard of over-fitting is
greater than for the simulations here and would likely produce less favorable results. Other directions for
further exploration of the relationships between sample size, numbers of informative and noninformative
features, true optimal error rate, and discovery and generalization error rates include the following: gen-
eration of data from distributions that are unknown to the learning method (i.e. non-normal), further
development of the relationship between false discovery rates and pattern discovery power, and further
theoretical development of accurate approximations and/or efficient simulations.
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